Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...

We recently compiled a list of the 10 stocks that will make you rich in 5-10 years. In this article, we are going to take a ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best rising ...

We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...

We recently compiled a list of the 10 Most Promising Growth Stocks According to Hedge Funds. In this article, we are going to ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in ...